Protara Therapeutics (TARA) AI Stock Analysis

• Market Cap: $270.55M
• Dividend Yield: N/A
• Average Volume (3M): 975.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: N/A
• EPS Growth: 48.84%
• Country: US
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 51,630,737
• 10 Day Avg. Volume: 697,652
• 30 Day Avg. Volume: 975,948
• PEG Ratio: 0.06
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.03
• Enterprise Value/Market Cap: 0.20
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -623.52
• Enterprise Value/Ebitda: -0.97
• 1Y Price Target: $24.83
• Price Target Upside: 373.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $5.50 ▲(4.96% Upside)

The score is primarily held back by weak financial performance driven by no revenue, sizable losses, and elevated cash burn. Technicals also lean soft with price below key short-term averages and negative MACD. Offsetting some of this, recent corporate events are constructive, including new funding and encouraging Phase 2 updates with supportive FDA feedback.

Positive Factors

Clinical Trial Success

The positive Phase 2 trial results for TARA-002 indicate significant clinical potential, enhancing the company's prospects in treating NMIBC and potentially leading to future revenue streams.

Financial Stability

A strong equity position and low debt levels provide financial stability, reducing insolvency risk and offering a solid foundation for future growth and investment in R&D.

Innovative Product Pipeline

Protara's focus on transformative therapies for significant unmet medical needs positions it well in the biotech industry, potentially leading to breakthroughs that can drive long-term growth.

Negative Factors

Lack of Revenue

The absence of revenue highlights challenges in achieving profitability, which is critical for sustaining operations and funding ongoing R&D efforts without relying heavily on external financing.

Cash Burn

High R&D expenses lead to negative cash flows, necessitating reliance on financing activities, which could result in future funding challenges and potential shareholder dilution.

High-Risk Profile

The high-risk nature of early-stage biotech, with no revenue and persistent cash outflows, poses significant challenges, impacting the company's ability to sustain long-term operations without successful product commercialization.

Protara Therapeutics Business Overview & Revenue Model

Company Description

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

How the Company Makes Money

Protara Therapeutics primarily makes money through the development and commercialization of its investigational therapies. The company's revenue model is centered around advancing its clinical-stage products through the regulatory approval process to eventually bring them to market. Key revenue streams include potential future sales of approved products, licensing agreements, and partnerships with other pharmaceutical companies. Additionally, the company may receive milestone payments and royalties if its therapies are successfully commercialized by partners. Significant factors contributing to its earnings include the successful advancement of its clinical trials, favorable regulatory outcomes, and strategic collaborations that provide funding and resources for product development.

Protara Therapeutics Financial Statement Overview

Summary

Protara Therapeutics exhibits typical financials of an early-stage biotech firm, with no revenue and significant R&D expenses. The strong equity position and low debt offer some stability, but the lack of revenue and ongoing cash burn are critical challenges.

Income Statement

Protara Therapeutics has consistently reported zero revenue over the years, which is typical for early-stage biotechnology firms focused on research and development. However, the absence of revenue and persistent negative EBIT and net income highlight significant challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with minimal debt, reflected in a low debt-to-equity ratio. This indicates financial stability and a low risk of insolvency. However, the ongoing cash burn without revenue generation poses potential risks for long-term sustainability.

Cash Flow

Negative operating and free cash flows are consistent with high R&D expenditure typical for biotechnology firms. However, the reliance on financing activities to sustain operations raises concerns about future funding needs and dilution risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-88.00K	0.00	-341.00K	0.00	0.00	-196.00K
EBITDA	-56.43M	-48.82M	-43.27M	-64.57M	-45.40M	-33.78M
Net Income	-52.90M	-44.60M	-40.42M	-65.95M	-47.25M	-33.98M
Balance Sheet
Total Assets	144.64M	181.45M	78.95M	113.29M	172.60M	203.16M
Cash, Cash Equivalents and Short-Term Investments	132.67M	170.29M	65.58M	84.37M	91.23M	168.60M
Total Debt	3.66M	4.48M	5.47M	6.38M	7.24M	1.09M
Total Liabilities	12.35M	14.32M	10.63M	11.21M	10.68M	3.91M
Stockholders Equity	132.29M	167.13M	68.32M	102.08M	161.91M	199.24M
Cash Flow
Free Cash Flow	-48.79M	-35.87M	-37.60M	-26.58M	-35.10M	-24.29M
Operating Cash Flow	-48.72M	-35.81M	-37.56M	-26.46M	-34.50M	-23.41M
Investing Cash Flow	-90.08M	19.16M	53.11M	14.95M	-98.19M	2.83M
Financing Cash Flow	99.60M	139.87M	-91.00K	-90.00K	-228.00K	189.40M

Protara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.24
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARA, the sentiment is Negative. The current price of 5.24 is below the 20-day moving average (MA) of 5.42, below the 50-day MA of 5.71, and above the 200-day MA of 4.14, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 44.16 is Neutral, neither overbought nor oversold. The STOCH value of 54.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TARA.

Protara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	59 Neutral	$168.88M	29.06	12.64%	―	35.42%	―
ZURA	55 Neutral	$335.52M	-7.29	-47.85%	―	―	-19.69%
OBIO	52 Neutral	$263.13M	-2.35	-166.97%	―	6.46%	-14.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TARA	48 Neutral	$270.55M	-3.41	-49.42%	―	―	48.84%
SKYE	48 Neutral	$30.17M	-0.76	-94.31%	―	―	-53.18%
HURA	46 Neutral	$43.43M	-1.12	-418.06%	―	―	99.21%

Protara Therapeutics Corporate Events

Protara Therapeutics Raises $86.3 Million in Offering

On December 8, 2025, Protara Therapeutics completed a public offering of 13,043,479 shares of common stock at $5.75 per share, raising approximately $86.3 million in gross proceeds. The funds are intended to support the clinical development of TARA-002 and other programs, as well as general corporate purposes, potentially strengthening the company’s position in the biopharmaceutical industry.

The most recent analyst rating on (TARA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.

Protara Therapeutics Completes $75 Million Stock Offering

On December 4, 2025, Protara Therapeutics entered into an Underwriting Agreement with several underwriters to sell 13,043,479 shares of common stock at $5.75 per share, closing the offering on December 8, 2025. The company expects to raise approximately $75 million in gross proceeds, which will be used to fund the clinical development of TARA-002 and other programs, as well as for general corporate purposes.

The most recent analyst rating on (TARA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.

Protara Therapeutics Announces Promising Phase 2 Trial Results

On December 3, 2025, Protara Therapeutics announced updated interim data from their Phase 2 ADVANCED-2 Trial of TARA-002, presented at the Society of Urologic Oncology Conference. The trial results showed promising complete response rates in BCG-Naïve NMIBC patients, with a 72% CR rate at any time and a favorable safety profile. The FDA has provided feedback supporting a registrational trial design for TARA-002 in BCG-Naïve patients, indicating potential expansion of its use beyond BCG-Unresponsive NMIBC. This development could significantly impact Protara’s market positioning and offer new treatment options for patients.

The most recent analyst rating on (TARA) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.

Protara Therapeutics Announces Promising Phase 2 Trial Results

On November 19, 2025, Protara Therapeutics announced interim results from its Phase 2 STARBORN-1 clinical trial of TARA-002 for pediatric patients with lymphatic malformations. The data indicated that the majority of evaluable patients achieved clinical success, with no serious adverse events reported. This development highlights the potential of TARA-002 to address a significant unmet need in treating macrocystic and mixed-cystic LMs, potentially positioning Protara as a leader in this rare disease market.

The most recent analyst rating on (TARA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.